

Front Line in T2D Advancing Care With Basal Insulin Excellence

TUESDAY, JULY 14, 2026 | 12:00 PM – 1:00 PM ET

HYBRID 

FACULTY



Jennifer B. Green, MD
Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina



Lucia M. Novak, MSN, CRNP, ANP-BC, BC-ADM, FAANP
President
Diabetes
North Bethesda
Co-Executive Director, Capital Health and Metabolic Center
of Capital Diabetes and Endocrine Associates
Silver Spring, Maryland

AGENDA

Welcome

Guideline-Based Use of Basal Insulin in T2D

Initiation and Titration: Practical Approaches

Addressing Barriers: Adherence, Hypoglycemia, and Injection Burden

New and Emerging Therapies: Once-Weekly Basal Insulin

Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of primary care physicians, nurse practitioners, and physician assistants, who play an important role in improving care for people with type 2 diabetes (T2D).

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Identify guideline- and evidence-based strategies for using basal insulin to treat people with T2D
- Apply guidelines and evidence for initiating and titrating basal insulin in people with T2D
- Determine clinical trial data supporting use of new/emerging once-weekly basal insulin for people with T2D
- Demonstrate improved confidence in their ability to initiate and titrate basal insulin safely and effectively to improve outcomes in people with T2D

ACCREDITATION STATEMENT

Medscape



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

FACULTY

Jennifer B. Green, MD, has the following relevant financial relationships:
Consultant or advisor for: Aqua; AstraZeneca; Bayer; BDI; Boehringer Ingelheim; Fractyl; Lilly; Novo Nordisk; Roche; Sparrow; Vertex; vTv; Zealand
Contracted researcher for: Boehringer Ingelheim; Cour; GentiBio; Merck; Metsera
Stock options from: BDI Inc

Lucia M. Novak, MSN, CRNP, ANP-BC, BC-ADM, FAANP, has the following relevant financial relationships:
Consultant or advisor for: Abbott Diabetes Care; Boehringer Ingelheim; Novo Nordisk; Sanofi US
Speaker or member of speakers bureau for: Abbott Diabetes Care; Novo Nordisk; Sanofi US

MEDSCAPE STAFF

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred in the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.



SCAN TO EARN YOUR CREDIT:

Or visit the CME certificate page by **August 11, 2026**

www.medscape.org/symposium/diabetes-foundational-2-credit